TrueBinding Overview
- Year Founded
-
2016

- Status
-
Private
- Employees
-
75

- Latest Deal Type
-
Series D1
- Latest Deal Amount
-
$57.7M
- Investors
-
1
TrueBinding General Information
Description
Developer of antibody drugs designed for applications in immune oncology and other disease areas. The company's drugs offer novel ligands to receptors of known checkpoint inhibitor pathways and an artificial intelligence and big data technology-powered platform, providing patients with anti-cancer immunotherapy and targetted anti-body drug delivery.
Contact Information
Website
www.truebinding.comCorporate Office
- 300 Lincoln Centre Drive
- Suite 200
- Foster City, CA 94404
- United States
Corporate Office
- 300 Lincoln Centre Drive
- Suite 200
- Foster City, CA 94404
- United States
TrueBinding Timeline
TrueBinding Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series D1) | 20-Jun-2023 | $57.7M | Completed | Clinical Trials - Phase 2 | ||
3. Later Stage VC (Series D) | 03-Nov-2022 | Completed | Clinical Trials - Phase 2 | |||
2. Later Stage VC (Series C) | 16-Jun-2022 | $100M | $150M | Completed | Clinical Trials - Phase 2 | |
1. Early Stage VC (Series B) | 13-Jul-2020 | $49.7M | $49.7M | Completed | Clinical Trials - Phase 2 |
TrueBinding Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | ||||||||
Series B | ||||||||
Series A | 30,000,000 | $0.000010 | $0.1 | $0.1 | 1x | $0.1 | 22.68% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
TrueBinding Patents
TrueBinding Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240352131-A1 | Methods of treating eye disease | Pending | 18-Apr-2023 | ||
US-20230279120-A1 | Methods of treating or inhibiting cardiovascular diseases | Pending | 09-Nov-2021 | ||
AU-2022388722-A1 | Methods of treating or inhibiting cardiovascular diseases | Pending | 09-Nov-2021 | ||
CA-3238590-A1 | Methods of treating or inhibiting cardiovascular diseases | Pending | 09-Nov-2021 | ||
EP-4429701-A1 | Methods of treating or inhibiting cardiovascular diseases | Pending | 09-Nov-2021 | C07K16/2851 |
TrueBinding Signals
TrueBinding Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
ShangBay Capital | Venture Capital | Minority |
TrueBinding FAQs
-
When was TrueBinding founded?
TrueBinding was founded in 2016.
-
Where is TrueBinding headquartered?
TrueBinding is headquartered in Foster City, CA.
-
What is the size of TrueBinding?
TrueBinding has 75 total employees.
-
What industry is TrueBinding in?
TrueBinding’s primary industry is Drug Discovery.
-
Is TrueBinding a private or public company?
TrueBinding is a Private company.
-
What is TrueBinding’s current revenue?
The current revenue for TrueBinding is
. -
How much funding has TrueBinding raised over time?
TrueBinding has raised $228M.
-
Who are TrueBinding’s investors?
ShangBay Capital has invested in TrueBinding.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »